Standard Curve

Log Concentration 9 8 7 6 5 4 3 2 1 0

Cro

ssin

g Po

int

40 35 30 25 20 15 10

LyoBeadProbeMasterMix

• Genotyping

In-houseTaqManassayforParvovirusB19.3-folddetermina@ononaplasmiddilu@onseries(30-9045-01).109-100copies/rxnweretested.

Cp(Mean) SD109 8,7 0,03108 12,1 0,01107 15,5 0,03106 19,0 0,06105 22,4 0,03104 25,8 0,04103 29,2 0,14100 32,5 0,6310 36,4 0,561 39,1 0,47

Melting Peaks

Temperature (°C) 74 72 70 68 66 64 62 60 58 56 54 52 50 48 46 44 42 40

-(d/d

T) F

luor

esce

nce

(498

-640

)

1,025

0,925

0,825

0,725

0,625

0,525

0,425

0,325

0,225

0,125

0,025

-0,075

-0,175

controlDNAwild-typemutant

heterozygousNTC

Melting Peaks

Temperature (°C) 74 72 70 68 66 64 62 60 58 56 54 52 50 48 46 44 42 40

-(d/d

T) F

luor

esce

nce

(498

-640

)

1,130

1,030

0,930

0,830

0,730

0,630

0,530

0,430

0,330

0,230

0,130

0,030

-0,070

-0,170

Amplification Curves

Cycles 45 40 35 30 25 20 15 10 5

Fluo

resc

ence

(465

-510

)

35,849 32,349 28,849 25,349 21,849 18,349 14,849 11,349 7,849 4,349 0,849

• Linearamplifica@onoveraminimumof9logarithmicsteps

TestedonMCM6C-13910Tmuta@onforlactosetolerance/intolerancewiththeLightMix®KitLactoseIntolerance(40-0307-32) byTIB-Molbiolaccordingtomanualspecifica@ons.Thecontrolsarepartofthekit,furthermore8DNAsamples(2xwt,3xmut,3xhet)weretested.

Amplification Curves

Cycles 50 45 40 35 30 25 20 15 10 5

Fluo

resc

ence

(498

-660

)

3,987 3,587 3,187 2,787 2,387 1,987 1,587 1,187 0,787 0,387

-0,013

Amplification Curves

Cycles 50 45 40 35 30 25 20 15 10 5

Fluo

resc

ence

(498

-640

)

9,133 8,233 7,333 6,433 5,533 4,633 3,733 2,833 1,933 1,033 0,133

Amplification Curves

Cycles 50 45 40 35 30 25 20 15 10 5

Fluo

resc

ence

(498

-640

)

9,042 8,142 7,242 6,342 5,442 4,542 3,642 2,742 1,842 0,942 0,042

LyoBeadProbeMasterMix• Hybridisa@onProbeAssays(LC-probes)

Amplification Curves

Cycles 45 40 35 30 25 20 15 10 5

Fluo

resc

ence

(498

-640

) 5,285 4,785 4,285 3,785 3,285 2,785 2,285 1,785 1,285 0,785 0,285

b)Amplification Curves

Cycles 50 40 30 20 10

Fluo

resc

ence

(498

-660

)

2,733 2,533 2,333 2,133 1,933 1,733 1,533 1,333 1,133 0,933 0,733 0,533 0,333 0,133 -0,067

c)Amplification Curves

Cycles 45 40 35 30 25 20 15 10 5

Fluo

resc

ence

(498

-640

)

6,672 6,072 5,472 4,872 4,272 3,672 3,072 2,472 1,872 1,272 0,672 0,072

a)

d)c)

b)a)

Amplification Curves

Cycles 50 45 40 35 30 25 20 15 10 5

Fluo

resc

ence

(498

-660

)

3,940 3,540 3,140 2,740 2,340 1,940 1,540 1,140 0,740 0,340

-0,060

A)TestedonT. vaginaliswith the LightMix®KitTrichomonasvaginalis (40-0610-32) byTIB-Molbiolaccordingtomanualspecifica@ons.Thestandardseriesforquan@ta@vesampledetermina@onarepartofthekit,furthermore6DNAsamplesweretested.

a)Standardseries106-10copies/rxn(LC640);b)T.vaginalisposi@veDNAsamples(LC640);c)internalPCRcontrol(LC660)

B)TestedonB. pertussis/B. parapertussiswith thedual-color LightMix®KitBordetella pertussis andparapertussis(40-0575-32) byTIB-Molbiolaccordingtomanualspecifica@ons.Thestandardseriesforquan@ta@vesampledetermina@onarepartofthekit,furthermore6DNAsamplesweretested(4xB.pert,2xB.para).

a)StandardseriesforB.pertussis106-10copies/rxn(LC640);b)B.pertussisposi@veDNAsamples(LC640);c)StandardseriesforB.parapertussis106-10copies/rxn(LC660);d)B.parapertussisposi@veDNAsamples(LC660)

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(618

-660

)

10,969 9,969 8,969 7,969 6,969 5,969 4,969 3,969 2,969 1,969 0,969

-0,031

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(440

-488

)

84,032 76,032 68,032 60,032 52,032 44,032 36,032 28,032 20,032 12,032 4,032

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(440

-488

)

77,039 70,039 63,039 56,039 49,039 42,039 35,039 28,039 21,039 14,039 7,039 0,039

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(533

-580

)

72,332 65,332 58,332 51,332 44,332 37,332 30,332 23,332 16,332

9,332 2,332

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(533

-580

)

52,350 47,350 42,350 37,350 32,350 27,350 22,350 17,350 12,350 7,350 2,350

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(533

-580

) 64,549 58,549 52,549 46,549 40,549 34,549 28,549 22,549 16,549 10,549 4,549

LyoBeadProbeMasterMix• Hydrolysisprobeassays(TaqMan™)

b)

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(618

-660

)

15,622 14,122 12,622 11,122 9,622 8,122 6,622 5,122 3,622 2,122 0,622

c)

e)c)

b)a)

d)

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(533

-580

)

61,324 55,324 49,324 43,324 37,324 31,324 25,324 19,324 13,324 7,324 1,324

a)

A)TestedwasonT.vaginaliswiththeLightMix®ModularTrichomonasvaginalisRepeatDNA(n°07696191 001) by Roche according tomanual specifica@ons. The standard series was created from theplasmid30-9472-02fromGenExpress,theposi@vecontrol(blackamplifica@oncurve)ispartofthekit,furthermore6DNAsamplesweretested.

a)Standardseries106-10copies/rxn;b)T.vaginalisposi@veDNAsamplesandposi@vecontrol;c)DNAextrac@oncontrolPhHV

B)TestedonB.pertussis/B.parapertussisinatriplexapproachwiththeLightMix®ModularBordetellapertussis(n°07730543001)andBordetellaparapertussis(n°07730004001)byRocheaccordingtomanual specifica@ons. The standard series were created from plasmid 30-7099-01 (B. pert) and30-8589-01(B.para)fromGenExpress,theposi@vecontrols(blackamplifica@oncurves)arepartofthekit,furthermore6DNAsamplesweretested(4xB.pert,2xB.para).

a)StandardseriesforB.pertussis106-10copies/rxn;b)B.pertussisposi@veDNAsamplesandposi@vecontrol;c)StandardseriesforB.parapertussis106-10copies/rxn;d)B.parapertussisposi@veDNAsamplesandposi@vecontrol;e)DNAextrac@oncontrolPhHV

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(533

-610

)

17,000 15,500 14,000 12,500 11,000

9,500 8,000 6,500 5,000 3,500 2,000 0,500

LyoBeadProbeMasterMix• Hydrolysisprobeassays(TaqMan™)

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(440

-488

)

58,502 53,502 48,502 43,502 38,502 33,502 28,502 23,502 18,502 13,502

8,502 3,502

-1,498

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(465

-510

)

30,849 27,849 24,849 21,849 18,849 15,849 12,849

9,849 6,849 3,849 0,849

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(533

-580

)

42,615 38,615 34,615 30,615 26,615 22,615 18,615 14,615 10,615

6,615 2,615

a) b)

c) d)

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(533

-640

)

28,959 26,459 23,959 21,459 18,959 16,459 13,959 11,459

8,959 6,459 3,959 1,459

Amplification Curves

Cycles 40 30 20 10

Fluo

resc

ence

(618

-660

)

10,002 9,002 8,002 7,002 6,002 5,002 4,002 3,002 2,002 1,002 0,002

e) f)

C) Tested on ESBL carbapenemase in a hexaplex approach with LightMix® Modular VIMcarbapenemase (n° 07 042 370 001), NDM-1 carbapenemase (n° 07 042 299 001), OXA-48carbapenemase(n°07042302001),KPCcarbapenemase(n°07042272001)andIMPcarbapenemase(n°07042345001) byRocheaccordingtomanualspecifica@ons.Thestandardserieswerecreatedfrom plasmids 30-8896-02 (VIM), 30-8439-01 (NDM-1), 30-8823-01 (OXA-48), 30-8799-01 (KPC) and30-8892-02(IMP)byGenExpress.

a)StandardseriesforVIM106-10copies/rxnb)StandardseriesforNDM-1106-10copies/rxnc)StandardseriesforOXA-48106-10copies/rxn

d)StandardseriesforKPC106-10copies/rxne)StandardseriesforIMP106-10copies/rxnf)DNAextrac@oncontrolPhHV